In a recent article for The Observer I noted that almost all the major drug companies had closed down their neuroscience divisions as evidence for a move away from a 'chemical-based' to a 'circuit-based' approach to treatments.
So to my surprise, a new Nature News article has just appeared discussing the re-launch of pharmaceutical giant Novartis's neuroscience section.
However, as I read the beginning of the article, it seems they are just banking on the fact that they can design drugs good enough to hit individual brain circuits.
Well. Best of luck with that.
|

We might think art experts and artists have a leg up on art appreciation that rewards them with a deeper enjoyment of art. But it turns out art literacy makes little difference in how much one appreciates art works. This was one finding from a recent study done with nearly 600 museum visitors that ranged from art experts to regular members of the public who may have only had limited engagement with art.
Researchers had volunteers wear a glove that not only tracked their movement through a Swiss art museum but also measured their heart rate and galvanic skin response (a measurement of sweat due to arousal) as they viewed individual pieces. And these measurements were then compared with survey responses—gathered after the visitors left the exhibition—that described how much they enjoyed different pieces within the exhibition./.../















